Page 3 - Robert Stott News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA granted Intercept Pharmaceuticals orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate intended for treatment of patients with primary biliary cholangitis. Obeticholic acid (Ocaliva, Intercept Pharmaceuticals) — a farnesoid X receptor agonist — was originally FDA approved for primary biliary cholangitis (PBC) in 2016 in combination with

The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors. Upadacitinib (Rinvoq, AbbVie)v is now indicated for both Crohn’s disease and ulcerative colitis. Additionally, this decision marks the drug’s

DESTIN, Fla. — Dermatomyositis and tinea are just two of many dermatologic complications that may resemble rheumatologic conditions, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Low disease activity and remission are achievable for patients with lupus if clinicians “minimize the prednisone” and administer adequate hydroxychloroquine, noted a speaker at the 2023 Congress of Clinical Rheumatology-East.

Padagis received FDA approval of its abbreviated new drug application for budesonide 2mg rectal foam for the induction of remission in patients with mild to moderate ulcerative colitis, according to a manufacturer release.The FDA has also designated Padagis’ product as a competitive generic therapy, which effectively prevents approval of other ANDAs for this indication for a period of 180